Hengrui Pharmaceuticals SGLT-2 inhibitor Heng grease net declared the listing.

Text . . . On September 30, Hengrui Pharma submitted a listed application for a new class of proline proline Hengle net tablets to be accepted by CDE.
is the first domestic SGLT-2 inhibitor to be declared on the domestic market.
proline hengle net tablets are suitable for the treatment of type 2 diabetes, the drug is in the development stage with the combination of Ebershatan drug intended for the treatment of type 2 diabetic nephropathy with combined hypertension.
According to the Pharmaceutical Rubik's Cube database NextPharma, there are currently eight SGLT-2 inhibitors approved for listing worldwide, of which Caglie Net (Johnson and Johnson), Dagle Net (AstraZeneca), Ingley Net (Blinger Ingelheim/Lilly) and Aglegon (Mercadon) have all been approved for listing in China, and the top three have all been negotiated for inclusion in the 2019 National Health Insurance Category B.
the most approved SGLT-2 inhibitors, Ingle has the highest net market share, with global sales of about $3.4 billion in 2019, according to public data released by the Company.
first half of 2020, Engele's net global sales were nearly $2 billion.
of the four SGLT-2 inhibitors currently approved in China, Engele Net has already approved two generic drugs from Haussen Pharmaceuticals and Colum Pharmaceuticals, and Kagle Net has two generic drugs approved by Haussen Pharmaceuticals and Zhengda Tianqing.
.